Neuroscience Letters 493 (2011) 76–79

Contents lists available at ScienceDirect

Neuroscience Letters

journal homepage: www.elsevier.com/locate/neulet

Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists

José L. Moreno[a], Terrell Holloway[a], Laura Albizu[b], Stuart C. Sealfon[b,d], Javier González-Maeso[a,b,c,*]

[a] Department of Psychiatry, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1229, New York, NY 10029, United States
[b] Department of Neurology, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1229, New York, NY 10029, United States
[c] Friedman Brain Institute, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1137, New York, NY 10029, United States
[d] Center for Translational Systems Biology, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1137, New York, NY 10029, United States

ARTICLE INFO

Article history:
Received 25 August 2010
Received in revised form 11 January 2011
Accepted 20 January 2011

Keywords:
Hallucinogenic drugs
LSD
Serotonin 5-HT2A receptor
Metabotropic glutamate mGlu2 receptor
G protein-coupled receptor (GPCR)
Schizophrenia and psychosis

ABSTRACT

Hallucinogenic drugs, including mescaline, psilocybin and lysergic acid diethylamide (LSD), act at serotonin 5-HT2A receptors (5-HT2ARs). Metabotropic glutamate receptor 2/3 (mGluR2/3) ligands show efficacy in modulating the responses induced by activation of 5-HT2ARs. The formation of a 5-HT2AR-mGluR2 complex suggests a functional interaction that affects the hallucinogen-regulated cellular signaling pathways. Here, we tested the cellular and behavioral effects of hallucinogenic 5-HT2AR agonists in mGluR2 knockout (mGluR2-KO) mice. Mice were intraperitoneally injected with the hallucinogens DOI (2 mg/kg) and LSD (0.24 mg/kg), or vehicle. Head-twitch behavioral response, expression of *c-fos*, which is induced by all 5-HT2AR agonists, and expression of *egr-2*, which is hallucinogen-specific, were determined in wild type and mGluR2-KO mice. [^{3}H]Ketanserin binding displacement curves by DOI were performed in mouse frontal cortex membrane preparations. Head twitch behavior was abolished in mGluR2-KO mice. The high-affinity binding site of DOI was undetected in mGluR2-KO mice. The hallucinogen DOI induced *c-fos* in both wild type and mGluR2-KO mice. However, the induction of *egr-2* by DOI was eliminated in mGlu2-KO mice. These findings suggest that the 5-HT2AR-mGluR2 complex is necessary for the neuropsychological responses induced by hallucinogens.

Hallucinogenic drugs, such as mescaline, psilocybin and lysergic acid diethylamide (LSD), induce profound alterations of human consciousness, emotion and cognition [12,16,27]. Inactivation of serotonin 5-HT2AR signaling by either genetic or pharmacological approaches results in markedly reduced behavioral responses to hallucinogenic drugs in both rodent models [10,18,34] and humans [33]. Thus, although hallucinogens bind other receptor subtypes [16], the 5-HT2A receptor is considered as necessary for the unique behavioral activity of these chemicals.

Metabotropic glutamate receptors mGlu2/3 have been the target of considerable attention regarding the molecular mechanism underlying psychosis [1,6,23,25]. We have recently reported that 5-HT2AR and mGluR2 are co-expressed in the same population of cortical neurons [14]. We found that 5-HT2AR and mGluR2 form a receptor complex in mouse and human brain, and activation of mGluR2 inhibits hallucinogen-specific neuronal signaling pathways [14]. Based on this and other findings [1,17,31], it has been proposed that mGluR2 agonists modulate, through a mechanism that requires the 5-HT2AR-mGluR2 complex, the signaling pathways induced by hallucinogenic 5-HT2AR agonists. Here we demonstrate that mice with disrupted mGluR2 signaling capacity (mGluR2-KO mice) are insensitive to the cellular and behavioral effects of hallucinogens. This observation suggests that the 5-HT2AR-mGluR2 complex, and not the 5-HT2AR alone, is the molecular target responsible for the actions of hallucinogenic drugs.

Experiments were performed on adult (10–14 weeks old) male 129S6/SvEv mice. 5-HT2A-KO mice have been previously described [18,19]. mGluR2-KO mice were obtained from the RIKEN BioResource Center, Japan (see [26,36] for details). mGluR2-KO mice were backcrossed for at least ten generations onto a 129S6/SvEv background. All subjects were offspring of heterozygote breeding. Animals were housed at 12 h light/dark cycle at 23 °C with food and water ad libitum. The Institutional Animal Use and Care Committee approved all experimental procedures. 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI; Sigma–Aldrich) was dissolved in saline and injected intraperitoneally (i.p.). Lysergic acid diethylamide (LSD; Sigma–Aldrich) was injected i.p. after suspension in a minimal amount of DMSO and made up to volume with normal saline.

Head-twitch behavior is known to be reliably and robustly elicited by hallucinogenic 5-HT2AR agonists in rodents [18,19].

* Corresponding author at: Department of Psychiatry, Mount Sinai School of Medicine, 1425 Madison Avenue, Box 1229, New York, NY 10029, United States. Tel.: +1 212 659 8873.
E-mail address: Javier.Maeso@mssm.edu (J. González-Maeso).

0304-3940/$ – see front matter © 2011 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.neulet.2011.01.046



Fig. 1. Behavioral response to hallucinogens DOI and LSD. Wild type and mGluR2-KO mice ($n = 4$–5 per treatment group) were injected with vehicle, DOI (2 mg/kg) or LSD (0.24 mg/kg), and the head-twitch response was scored 15 min after injection for 30 min. $^{***}p < 0.001$; Bonferroni's *post hoc* test of two-way ANOVA. Data are means ± S.E.M. n.s., not significant.



Fig. 2. Expression of 5-HT2AR in mGluR2-KO mice. [^{3}H]Ketanserin binding saturation curves in wild type (black) and mGluR2-KO (white) mouse frontal cortex membrane preparations ($n = 6$ per group). Data are means ± S.E.M.

We first assayed the head-twitch response induced by DOI and LSD in wild type and mGluR2-KO mice (Fig. 1). Two-way ANOVA indicated a statistical significance for the effects of the treatment [$F(2,19) = 31.05$; $p < 0.001$] and genotype [$F(1,19) = 74.10$; $p < 0.001$]. Significance was also found for the interaction between treatment and genotype [$F(2,19) = 20.05$; $p < 0.001$]. The *post hoc* analysis revealed that DOI and LSD activated a significant head-twitch response in wild type mice ($p < 0.001$). Notably, no significant head-twitch response was detected in mGluR2-KO mice for any of these two agonists ($p > 0.05$).

The decreased head-twitch response following administration of hallucinogens led us to examine the level of expression of 5-HT2AR in mGluR2-KO mice. Equilibrium binding saturation experiments were performed to determine the binding affinity (K_D) and receptor density (B_{max}) of 5-HT2ARs in wild type and mGluR2-KO mouse frontal cortex membrane preparations (Fig. 2; for experimental details, see [14]). Neither B_{max} nor K_D values of the binding of [^{3}H]ketanserin, a 5-HT2AR antagonist, were significantly changed in mGluR2-KO mice, which demonstrates that level of expression of 5-HT2AR is not affected in the absence of mGluR2 (B_{max}: wild type, 724.5 ± 93 fmol/mg protein; mGluR2-KO, 701.5 ± 80 fmol/mg protein. K_D: wild type, 2.27 ± 0.8 nM; mGluR2-KO, 2.30 ± 0.71 nM).

We next determined the affinity of the mGlu2/3 agonist LY379269 displacing [^{3}H]LY341495 in wild type and 5-HT2AR-KO mice (Fig. 3A), and that of the 5-HT2AR agonist DOI displacing [^{3}H]ketanserin binding in wild type and mGluR2-KO mice (Fig. 3B; for experimental details, see [14]). Competition binding experiments of [^{3}H]LY341495 were best described by a two-site model in wild type mouse frontal cortex membrane preparations [$F(2,28) = 4.71$; $p < 0.05$]. However, displacement of [^{3}H]LY341495 binding by LY379268 was best described by a one-site model in 5-HT2AR-KO mice [$F(2,16) = 0.62$; $p = 0.55$]. The low affinity binding site for LY379268 did not differ between wild type and 5-HT2AR-KO mice (Fig. 3A). Similarly, competition binding experiments of



Fig. 3. Cellular response to hallucinogenic 5-HT2AR agonist DOI. (A) LY379268 displacement of [^{3}H]LY341495 binding was performed in wild type (black) and 5-HT2AR-KO (white) mouse frontal cortex membrane preparations. Competition curves were analyzed by nonlinear regression to derive dissociation constants for the high and low affinity states of the receptor. One-site model or two-site model as a better description of the data was determined by *F* test. Two-site model, $p < 0.001$. A two-site model provided a better description of the data in wild type mice. Wild type mice: $K_{i\text{-high}}$ (log *M*), −9.51 ± 0.45; $K_{i\text{-low}}$ (log *M*), −7.95 ± 0.26; % high-affinity binding sites, 36.6 ± 1; and 5HT2AR-KO mice: $K_{i\text{-low}}$ (log *M*), −7.60 ± 0.07 ($n = 3$–5). (B) DOI displacement of [^{3}H]ketanserin binding was performed in wild type (black) and mGluR2-KO (white) mouse frontal cortex membrane preparations. A two-site model provided a better description of the data in wild type mice. Wild type mice: $K_{i\text{-high}}$ (log *M*), −8.56 ± 0.28; $K_{i\text{-low}}$ (log *M*), −6.31 ± 0.16; % high-affinity binding sites, 35.9 ± 4; and mGluR2-KO mice: $K_{i\text{-low}}$ (log *M*), −6.72 ± 0.08 ($n = 5$–6). (C) Cellular response in mouse frontal cortex assayed by qRT-PCR. Wild type or mGluR2-KO mice were injected with vehicle (white) or DOI (black; 2 mg/kg). Changes in expression levels are reported as fold change over vehicle. $^*p < 0.05$; $^{***}p < 0.001$; Bonferroni's *post-hoc* test of two-factor ANOVA ($n = 5$–6 per group). Data are means ± S.E.M. n.s., not significant.